About Hawkeye MRI AG
Our Nanobrite™ imaging agent has been under development for more than 12 years in the United States, first in the laboratory of Dr. Rodney Ho at the University of Washington Medical School, and then by Nova TheraNostics Inc., a privately held biotechnology in the State of Washington. The technology has recently been exclusively licensed to Hawkeye MRI AG for final clinical development and commercialization.
Hawkeye’s mission is to bring to market safe and superior imaging agents for the early detection of diseases using MRI. Because our technology has a longer dwell time in the vasculature, and because it results in dramatically enhanced organ imagery, less advanced MRI machines can also be utilized to achieve outstandingly clear images, thus increasing the technology's market size and appeal.
learn more
Our Team
A strong team of skilled people ensures the development progress for the project
JØRGEN THORBALL, MD
Chief Medical OfficerXOventure GmbH, founder of Rigi Care medical research & patient consulting and co-founder of ViroGates A/S listed at NASDAQ First North.
Dr. Thorball started his first two companies in the early 80s before he was headhunted to international corporate management positions in the pharmaceutical industry (Pharmacia and Sanofi Aventis) and the biotech industry (BioGaia AB and Novozymes A/S). Dr. Thorball has since 1996 been building companies from idea to exit, designing clinical studies and developed a range of medical products.
JOHN J. REDDINGTON, DVM, PhD
Chief Operating OfficerDr. Reddington recently served as President and Chief Executive Officer of Morris Animal Foundation. Before that he was the Chief Operating Officer for Cambridge Biomedical Inc., a privately held bioanalytical CRO. Previously he served as President and CEO of Sirtex Medical, Inc., the US division of an Australian publicly traded company Sirtex Medical Group Ltd. (ASX: SIR).
Prior to joining Sirtex, John was COO and SVP of R&D for the publicly traded company Valentis Inc., where he played a key role in transitioning Valentis’ clinical focus from gene therapy to poloxamer-based therapeutics to treat cardiovascular disease. In addition, he was responsible for selling off all non-critical assets to facilitate a reverse merger, and spun out the manufacturing division as an independent business unit. Previously, John founded DiagXotics Inc. and led it to become the world leader in disease diagnosis for the $52-billion global aquaculture market. Earlier in his career, John directed the build-out and operation of an office and cancer cell therapy laboratory for Greenwich Biotherapeutics Inc. a joint venture between Biotherapeutics Inc., Yale University and Greenwich Hospital. Dr Reddington received his B.A. from Rice University, his M.A. from the University of Texas, Arlington and his DVM and PhD from Washington State University.
ANNE M LANG
Director of OperationsMs. Lang has over 17 years of clinical research experience in the pharmaceutical industry, and an additional 3.5 years of experience with medical device studies. Most recently she was working as Senior Project Manager in the vaccines division of PPD, one of the world’s largest pharmaceutical CROs where she was responsible for the overall coordination and management of clinical projects from start up through to final deliverables. Earlier in her career she also worked for PPD as a Senior Clinical Research Associate, a role that she also served with Chiltern International LTd. Prior to joining PPD, Anne was a Clinical Project Manager at MediVector, Inc. where she led the cross-functional integration of all components of their clinical trial studies to meet timelines and budgets.
Ms. Lang has additional experience as a Research Scientist at Diagnostic Oncology CRO Inc., and DiagXotics Inc. Ms. Lang earned her Bachelors of Science degree in Biology from Southern Connecticut State University. She was certified as a Clinical Research Professional with the Society of Clinical Research Associates (SoCRA) and in Project Management at the University of Massachusetts.
RODNEY J HO, PhD, FAAPS, FAAAS
Scientific Advisory Board MemberDr. Ho is the Milo Gibaldi Endowed Professor of Pharmaceutics and Director of the DNA Sequencing and Gene Analysis Center at the University of Washington. He is the inventor of the HMRI platform technology and a co-founder of HMRI. Rodney also holds appointments at Clinical Pharmacology, Fred Hutchinson Cancer Research Center, the Center for AIDS and STD Research, the Center for Human Development and Disability, the Center for Ecogenetics at the University of Washington, and the Washington National Primate Research Center.
He is an elected Fellow and Chair of the American Association for the Advancement of Sciences. He is also an electded Fellow of the American Association of Pharmaceutical Scientists (AAPS). Dr. Ho’s accomplishments include six patents, over 90 peer-reviewed publications, 20 book chapters and he has edited two books. Rodney has received numerous honors, including AAPS’s Biotechnology lifetime Research Achievement and Paul Dawson lifetime contribution to education and research in Biotechnology awards, and has served as a consultant to pharmaceutical and biotechnology companies for over 20 years.
LARS KNØSGAARD JENSEN
CEOBorn in 1979 and with an early passion for numbers, Lars pursued this career graduating with an MSc in Finance from the University of Aarhus in Denmark.
He has over 20 years of experience managing assets and risks for UHNWIs and large multinational companies including select successful direct investments in early stage projects such as Hawkeye MRI.
Over 100 years of combined drug development experience of our senior staff
Nanobrite™ is being developed by international experts with a proven track record from discovery, patents, formulation, animal trials to clinical development, regulatory approval and market launch.
Over 100 years of combined drug development experience of our senior staff